LLY - Lantheus Point BioPharma drop amid results of SPLASH study on prostate cancer
2023-12-18 09:22:49 ET
More on Lantheus, POINT Biopharma Global, etc.
- POINT Biopharma Global: Why The Market Believes That A Second Bidder May Emerge
- Lantheus Holdings: Huge Catalysts Ahead And Cheap Valuation
- Lantheus Holdings, Inc. (LNTH) Q3 2023 Earnings Call Transcript
- Eli Lilly surprised as POINT Biopharma acquisition remains incomplete
- Eli Lilly further extends tender offer to buy Point Biopharma
For further details see:
Lantheus, Point BioPharma drop amid results of SPLASH study on prostate cancer